UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Korean, Japanese healthcare firms reaffirm ‘joint growth’ amid trade feud
by Jeong Sae-im
2019-07-17 14:06
Government faces uphill battle to look into Medytox over illicit drug
by Jeong Sae-im
2019-07-15 13:58
Doctors question Pexa-Vec+Imfinzi combo’s effect on colon cancer
by Jeong Sae-im, Kim Yun-mi
2019-07-12 15:13
Court suspends decision on ministry’s order to revoke Invossa license
by Jeong Sae-im
2019-07-12 13:11
Prosecutors raid 2 lead managers of Kolon TissueGene’s IPO
by Jeong Sae-im
2019-07-11 16:39
라인
NKMax America seeks NASDAQ listing
by Jeong Sae-im
2019-07-11 12:41
Contera Pharma gets ₩3 billion funding from venture capital
by Jeong Sae-im
2019-07-10 17:28
Psomagen seeks KOSDAQ listing using technology exception policy
by Jeong Sae-im
2019-07-10 15:20
Court to test Nabota’s spore-forming to end Daewoong-Medytoxin dispute
by Jeong Sae-im
2019-07-10 12:44
Kolon files administrative suit against Invossa license revocation
by Jeong Sae-im
2019-07-09 11:47
라인
SillaJen shareholders panic over exec’s selling of 160,000 stocks
by Jeong Sae-im
2019-07-09 11:45
Kolon TissueGene’s ₩490 billion shares on verge of becoming worthless
by Jeong Sae-im
2019-07-08 12:06
Dong-A ST, Dongwha Pharm lose status of innovative drugmaker
by Jeong Sae-im
2019-07-05 16:00
Victims question Kolon CEO’s sincerity in apology
by Jeong Sae-im
2019-07-05 15:14
Janssen nixes deal with Hanmi over antidiabetic obesity drug
by Jeong Sae-im
2019-07-04 10:52
라인
[News Focus]Yuhan pulled off $3.1 billion licensing deals in one year. How?
by Jeong Sae-im
2019-07-02 12:11
[Special]Korean drugmakers harbor undue expectations on global blockbusters
by Jeong Sae-im
2019-07-01 16:19
BNO BIO to invest $1 million in Israeli biotech venture
by Jeong Sae-im
2019-06-28 16:10
Shareholders in shock over HLB’s phase-3 trial setback
by Jeong Sae-im
2019-06-28 10:47
‘Food and drug ministry alone can’t handle Invossa debacle’
by Jeong Sae-im
2019-06-27 12:45
-
1
2
3
4
5
6
7
8
9
10
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top